Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vascular Endothelial Dysfunction in Sleep Apnea
NCT05289063Phase 1Recruiting
- Sponsor
- Columbia University
- Start
- Oct 2022
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of atorvastatin in obstructive sleep apnea (OSA) (2 arms), sponsored by Columbia University. Primary endpoints: Circulating levels of Angiopoietin-2 at 4 weeks and Interaction of ER-bound VAPB with late endosome-bound ORP1L at 4 weeks. Started Oct 2022; status: recruiting.
02
Drugs
atorvastatin
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT05289063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05289063.